Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with Type II diabetes

Diabetologia

Volumn 43, Issue 3, 2000, Pages 278-284

  Raskin, P ^a   Rappaport, E B ^b   Cole, S T ^b   Yan, Y ^b   Patwardhan, R ^b   Freed, M I ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Efficacy; Insulin resistance; Non esterified fatty acids; Rosiglitazone; Thiazolidinedione; Type II diabetes

Indexed keywords

GLUCOSE; ROSIGLITAZONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034098771     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250050045     Document Type: Article

References (21)

1. 1. DeFronzo RA (1988) The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37: 667-687
2. 2. DeFronzo RA (1992) Pathogenesis of Type 2 (non-insulin dependent) diabetes mellitus: a balanced overview. Diabetologia 35: 389-397
3. 3. Saltiel AR, Horikoshi H (1995) Thiazolidinediones are novel insulin-sensitizing agents. Curr Opin Endocrinol Diabetes 2: 341-347
4. 4. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 270: 12953-12956
5. 5. Willson TM, Cobb JE, Cowan DJ et al. (1996) The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 39: 665-668
6. 6. Patel J, Anderson RJ, Rappaport EB (1999) Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes, Obesity and Metabolism 1: 165-172
7. 7. National Diabetes Data Group (1979) Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28: 1039-1057
8. 8. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18: 499-502
9. 9. Mooradian AD, Thurman JE (1999) Drug therapy of post-prandial hyperglycaemia. Drugs 57: 19-29
10. 10. Hanefeld M, Temelkova-Kurktschiev T (1997) The post-prandial state and the risk of atherosclerosis. Diabet Med 14 [Suppl 3]:S6-S11
11. 11. Jackson CA, Yudkin JS, Forrest RD (1992) A comparison of the relationships of the glucose tolerance test and the glycated hemoglobin assay with diabetic vascular disease in the community. The Islington Diabetes Survey. Diabetes Res Clin Pract 17: 111-123
12. 12. Ohkubo Y, Kishikawa H, Araki E et al. (1995) Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28: 103-117
13. 13. Haller H (1997) Postprandial glucose and vascular disease. Diabet Med 14 [Suppl 3]:S50-S56
14. 14. Curb JD, Rodriguez BL, Burchfiel CM, Abbott RD, Chiu D, Yano K (1995) Sudden death, impaired glucose tolerance, and diabetes in Japanese American men. Circulation 91: 2591-2595
15. 15. Saltiel AR, Olefsky JM (1996) Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45: 1661-1669
16. 16. Fagot-Campagna A, Balkau B, Simon D et al. (1998) High free fatty acid concentration: an independent risk factor for hypertension in the Paris Prospective Study. Int J Epidemiol 27: 808-813
17. 17. Reaven GM (1988) Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 37: 1595-1607
18. 18. Dresner A, Laurent D, Marcucci M et al. (1999) Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 103: 253-259
19. 19. McGarry JD, Dobbins RL (1999) Fatty acids, lipotoxicity and insulin secretion. Diabetologia 42: 128-138
20. 20. Paolisso G, Howard BV (1998) Role of non-esterified fatty acids in the pathogenesis of type 2 diabetes mellitus. Diabet Med 15: 360-366
21. 21. Kumar S, Boulton AJM, Beck-Nielsen H et al. (1996) Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 39: 701-709